MARKET

HSKA

HSKA

Heska
NASDAQ

Real-time Quotes | Nasdaq Last Sale

97.00
-1.82
-1.84%
Closed 16:00 09/21 EDT
OPEN
97.02
PREV CLOSE
98.82
HIGH
97.37
LOW
93.90
VOLUME
33.23K
TURNOVER
--
52 WEEK HIGH
110.90
52 WEEK LOW
50.00
MARKET CAP
916.04M
P/E (TTM)
-57.1294
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Heska's (HSKA) CEO Kevin Wilson on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 20:20
Heska shares are trading lower despite reporting better-than-expected Q2 sales results.
Benzinga · 08/04 17:14
Heska EPS beats by $0.17, beats on revenue
Heska (NASDAQ:HSKA): Q2 Non-GAAP EPS of $0.00 beats by $0.17; GAAP EPS of -$0.72 misses by $0.37. Revenue of $45.71M (+62.4% Y/Y) beats by $5.01M. Press Re
seekingalpha · 08/04 17:10
Heska Q2 Sales $45.71M Beat $39.89M Estimate
Heska (NASDAQ:HSKA) reported quarterly sales of $45.71 million which beat the analyst consensus estimate of $39.89 million by 14.60 percent. This is a 62.41 percent increase over sales of $28.15 million the same period
Benzinga · 08/04 12:10
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:32
Heska Corporation Second Quarter 2020 Financial Results and Earnings Call Scheduled for August 4, 2020
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, plans to report its second quarter 2020 financial performance in a press release before the market opens on Tuesday, August
PR Newswire · 07/16 12:00
Hedge Funds Have Never Been This Bullish On Heska Corp (HSKA)
Insider Monkey · 06/28 21:20
Edited Transcript of HSKA earnings conference call or presentation 7-May-20 3:00pm GMT
Thomson Reuters StreetEvents · 06/15 14:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSKA stock price target is 101.17 with a high estimate of 116.50 and a low estimate of 77.00.
EPS
Institutional Holdings
Institutions: 179
Institutional Holdings: 10.50M
% Owned: 111.23%
Shares Outstanding: 9.44M
TypeInstitutionsShares
Increased
57
1.70M
New
33
-110.93K
Decreased
29
1.08M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.45%
Healthcare Equipment & Supplies
-1.43%
Key Executives
Chairman/Independent Director
Scott Humphrey
President/Chief Executive Officer/Director
Kevin Wilson
Chief Financial Officer/Executive Vice President
Catherine Grassman
Chief Operating Officer/Executive Vice President
Nancy Wisnewski
Executive Vice President/Chief Administrative Officer/General Counsel
Christopher Sveen
Executive Vice President
Jason Aroesty
Executive Vice President
Steven Eyl
Director
Stephen Davis
Independent Director
Mark Furlong
Independent Director
Sharon Larson
Independent Director
David Sveen
Independent Director
Bonnie Trowbridge
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/12/2012
Dividend USD 0.1
09/26/2012
05/07/2012
Dividend USD 0.1
06/27/2012
02/22/2012
Dividend USD 0.1
03/28/2012

Analyst Price Target

The average HSKA stock price target is 101.17 with a high estimate of 116.50 and a low estimate of 77.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HSKA
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Heska Corp stock information, including NASDAQ:HSKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSKA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSKA stock methods without spending real money on the virtual paper trading platform.